Kendra Wong
Comptroller/Controller/Auditor bei LENSAR, INC.
Vermögen: 123 892 $ am 30.04.2024
Profil
Kendra W.
Wong is currently working as the Principal Accounting Officer at LENSAR, Inc. She previously worked as the Assistant Controller-Subsidiary Operations at PDL BioPharma, Inc. from 2018 to 2021.
Ms. Wong holds an MBA from Arizona State University and an undergraduate degree from the University of California, Davis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LENSAR INC
0,32% | 06.05.2024 | 36 120 ( 0,32% ) | 123 892 $ | 30.04.2024 |
Aktive Positionen von Kendra Wong
| Unternehmen | Position | Beginn |
|---|---|---|
| LENSAR, INC. | Comptroller/Controller/Auditor | 11.01.2022 |
Ehemalige bekannte Positionen von Kendra Wong
| Unternehmen | Position | Ende |
|---|---|---|
| PDL BIOPHARMA, INC. | Corporate Officer/Principal | 01.03.2021 |
Ausbildung von Kendra Wong
| University of California, Davis | Undergraduate Degree |
| Arizona State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LENSAR, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
